Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00408421 · ClinicalTrials.gov registry record · Phase 3

Duloxetine Versus Placebo for Osteoarthritis Knee Pain

A Phase 3 study, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 3
Development phase
231
Enrollment target

NCT00408421 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 231 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00408421, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 3
Development phase
231 participants
Enrollment target

Study Summary

The primary purpose of this study is to determine if duloxetine reduces pain severity in patients with osteoarthritis knee pain.

Interventions

  • DRUG Duloxetine
  • DRUG placebo

Trial Details

FieldValue
Enrollment Target 231 participants
Start Date 2006-11
Est. Completion 2007-10
Phase Phase 3

Sponsor

Eli Lilly and Company

1,341 total trials

What the Registry Record Tells You About NCT00408421

The ClinicalTrials.gov registry entry for NCT00408421 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 231 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Duloxetine is the first listed.

NCT00408421 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00408421 about?

NCT00408421 is a clinical study titled "Duloxetine Versus Placebo for Osteoarthritis Knee Pain". The primary purpose of this study is to determine if duloxetine reduces pain severity in patients with osteoarthritis knee pain.

What is the current status of trial NCT00408421?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 231 participants. The study started on 2006-11. Estimated completion is 2007-10.

What interventions are being tested in trial NCT00408421?

The interventions under investigation include: Duloxetine (DRUG), placebo (DRUG).

Who is sponsoring clinical trial NCT00408421?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.